Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells

Becker KA, Carpinteiro A, Hoffmann M, Pöhlmann S, Kornhuber J, Gulbins E (2021)

Publication Type: Journal article

Publication year: 2021

Journal

STAR Protocols Cell Press

Book Volume: 2

Article Number: 100356

Journal Issue: 1

DOI: 10.1016/j.xpro.2021.100356

Abstract

This protocol enables the testing of drugs against infection of epithelial cells with SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), using pseudo-typed replication deficient vesicular stomatitis virus particles (pp-VSV) presenting the SARS-CoV-2 spike protein. After treating human volunteers with amitriptyline, an approved antidepressant and inhibitor of the acid sphingomyelinase, freshly isolated nasal epithelial cells were infected ex vivo and infection levels were quantified. This protocol offers the possibility to rapidly test the efficacy of potential drugs in the fight against COVID-19. For complete details on the use and execution of this protocol, please refer to Carpinteiro et al. (2020).

Authors with CRIS profile

Johannes Kornhuber Lehrstuhl für Psychiatrie und Psychotherapie

Involved external institutions

Universität Duisburg-Essen (UDE) DE Germany (DE) Deutsches Primatenzentrum (DPZ), Leibniz-Institut für Primatenforschung DE Germany (DE)

How to cite

APA:

Becker, K.A., Carpinteiro, A., Hoffmann, M., Pöhlmann, S., Kornhuber, J., & Gulbins, E. (2021). Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells. STAR Protocols, 2(1). https://doi.org/10.1016/j.xpro.2021.100356

MLA:

Becker, Katrin Anne, et al. "Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells." STAR Protocols 2.1 (2021).

BibTeX: Download